First clinic research study of China's most focused candidate on oral drug for Omicron published - Global Times

The first clinic research of China's antiviral oral drug against SARS-CoV-2, VV116, was published on Tuesday. The study shows the drug can effectively treat patients infected with the Omicron variant with mild symptoms in early stages.

A medic takes a swab sample from a resident for nucleic acid test at a community in Haidian District of Beijing, capital of China, May 13, 2022. Beijing has started three additional rounds of mass nu… [+2256 chars]

full article...